


## VU 0364439

<b>Cat. No.:</b>	HY-15476		
<b>CAS No.:</b>	1246086-78-1		
<b>Molecular Formula:</b>	C <sub>18</sub> H <sub>13</sub> Cl <sub>2</sub> N <sub>3</sub> O <sub>3</sub> S		
<b>Molecular Weight:</b>	422.29		
<b>Target:</b>	mGluR		
<b>Pathway:</b>	GPCR/G Protein; Neuronal Signaling		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 50 mg/mL (118.40 mM; Need ultrasonic)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.3680 mL	11.8402 mL	23.6804 mL
		5 mM	0.4736 mL	2.3680 mL	4.7361 mL
10 mM		0.2368 mL	1.1840 mL	2.3680 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution  2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.92 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	VU 0364439 is a mGlu4 positive allosteric modulator (PAM), with EC50 of 19.8 nM. IC50 Value: 19.8 nM (EC50) Target: mGluR in vitro; in vivo: VU 0364439 possess less than ideal PK properties preventing their use as in vivo tools. It shows better stability in HLM (63% remaining) than RLM (2% remaining).
<b>IC<sub>50</sub> &amp; Target</b>	mGlu4 Receptor 19.8 nM (EC50)

### REFERENCES

---

[1]. Hong, Sang-Phyo; Liu, Kevin G.; Ma, Gil et al. Tricyclic Thiazolopyrazole Derivatives as Metabotropic Glutamate Receptor 4 Positive Allosteric Modulators. *Journal of Medicinal Chemistry* (2011), 54(14), 5070-5081.

[2]. Engers, Darren W.; Gentry, Patrick R.; Williams, Richard et al. Synthesis and SAR of novel 4-(phenylsulfamoyl)phenylacetamide mGlu4 positive allosteric modulators (PAMs) identified by functional high-throughput screening (HTS). *Bioorganic & Medicinal Chem*

[3]. AJ Robichaud et al. Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS Therapeutics. *ACS Chem. Neurosci.* 2011, 2(8), 433-449.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA